Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model

Liebig, Catherine; Agarwal, Neeti; Ayala, Gustavo; Verstovsek, Gordana; Tuszynski, George P.; Albo, Daniel

doi:10.1016/j.jss.2007.02.036

Cited by 7 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, the anti-tumor activity of this molecule is specifically mediated in its TSP1 binding site. (72,73)…”

Section: Therapeutics Effects Of Tsp1 Derived Peptides In Intestinal mentioning

confidence: 99%

The Role of Thrombospondin 1 on Intestinal Inflammation and Carcinogenesis

Gutierrez

2008

Biomark�Insights

View full text Add to dashboard Cite

Crohn’s disease and ulcerative colitis are inflammatory bowel diseases (IBD) quite common in the United States and other Western countries. Patients suffering IBD are at greater risk of developing colorectal adenocarcinoma than the general population. Both, the adenomacarcinoma and the inflammation-carcinogenesis processes are characterized by active angiogenesis. Recent studies also have shown that anti-angiogenesis might be a novel therapeutic approach for IBD. Thrombospondin 1 (TSP1) is an extracellular protein well known for its anti-angiogenic properties. TSP1 also has key functions in inflammation, which is assumed to be the primary cause for carcinogenesis in IBD. This review is focused on the role of TSP1 in colorectal carcinogenesis. The therapeutic effects of TSP derived-peptides on inhibiting the inflammation-carcinogenesis progression are also discussed.

show abstract

“…In that study, the anti-tumor activity of this molecule is specifically mediated in its TSP1 binding site. (72,73)…”

Section: Therapeutics Effects Of Tsp1 Derived Peptides In Intestinal mentioning

confidence: 99%

The Role of Thrombospondin 1 on Intestinal Inflammation and Carcinogenesis

Gutierrez

2008

Biomark�Insights

View full text Add to dashboard Cite

show abstract

“…Furthermore, a number of these genes were correlated with cancer (20,21,24,(31)(32)(33)(34). The expression of the most significant of these genes must be characterized and explored in CRC cells (21,35,36).…”

Section: Discovery Of Genes From Feces Correlated With Colorectal Canmentioning

confidence: 99%

Discovery of genes from feces correlated with colorectal cancer progression

et al. 2016

View full text Add to dashboard Cite

Abstract. Colorectal cancer (CRC) is considered to develop slowly via a progressive accumulation of genetic mutations. Markers of CRC may serve to provide the basis for decision-making, and may assist in cancer prevention, detection and prognostic prediction. DNA and messenger (m)RNA molecules that are present in human feces faithfully represent CRC manifestations. In the present study, exogenous mouse cells verified the feasibility of total fecal RNA as a marker of CRC. Furthermore, five significant genes encoding solute carrier family 15, member 4 (SLC15A4), cluster of differentiation (CD)44, 3-oxoacid CoA-transferase 1 (OXCT1), placenta-specific 8 (PLAC8) and growth arrest-specific 2 (GAS2), which are differentially expressed in the feces of CRC patients, were verified in different CRC cell lines using quantitative polymerase chain reaction. The present study demonstrated that the mRNA level of SLC15A4 was increased in the majority of CRC cell lines evaluated (SW1116, LS123, Caco-2 and T84). An increased level of CD44 mRNA was only detected in an early-stage CRC cell line, SW1116, whereas OXCT1 was expressed at higher levels in the metastatic CRC cell line CC-M3. In addition, two genes, PLAC8 and GAS2, were highly expressed in the recurrent CRC cell line SW620. Genes identified in the feces of CRC patients differed according to their clinical characteristics, and this differential expression was also detected in the corresponding CRC cell lines. In conclusion, feces represent a good marker of CRC and can be interpreted through the appropriate CRC cell lines. IntroductionColorectal cancer (CRC) is considered to develop slowly via the progressive accumulation of genetic mutations (1,2). Genes that regulate cell growth and differentiation must be altered in cancerous cells in the process of tumorigenesis (3,4). Markers of CRC may provide the basis for decision-making regarding intensive chemotherapy or molecule-targeting drugs in CRC patients (5-7). Therefore, the identification of markers may assist in cancer prevention, detection and prognostic prediction (5,8,9), thereby increasing survival rates (10). Molecular markers (11) have their own clinical significance in CRC (12).In CRC, both sigmoidoscopy and colonoscopy are considered to be the gold standards regarding detection rates. However, these clinical examinations have drawbacks in terms of their risk and inconvenience (13,14

show abstract

“…Soluble peptides that bind to α 2 β 1 integrins at the RGD motif are therefore able to prevent cell attachment and thus induce apoptosis (Buckley et al, 1999). In vitro angiocidininhibitory peptide trials have been demonstrated to be well tolerated and to reduce cancer burden in murine colon cancer models, with reductions in primary tumour volume and tumour burden (Liebig et al, 2007). Table 1.…”

Section: Rgd Peptide / Disintegrin Based Therapiesmentioning

confidence: 99%

“…Broad spectrum antitumour activity in seven cell lines and murine models (Funahashi et al, 2002), (Semba et al, 2004) (Sabherwal et al, 2006), (Liebig et al, 2007) HYD-1 D-amino acid peptide α 6 β 1 DU145 prostate carcinoma cell line (DeRoock et al, 2001), (Cheresh and Spiro, 1987) Endorepellin C-terminus of perlecan protein α 2 , α 2 β 1 Lewis lung carcinoma model, HT1080 and A431 cell lines (Bix et al, 2007), (Woodall et al, 2008) Perlecan Heparan sulfate proteoglycan α 2 β 1 C4-2B and HT1080 cell lines (Savore et al, 2005), (Mathiak et al, 1997) HA 1/29 Monoclonal antibody α 2 , α 2 β 1 Human dermal endothelial cells (Senger et al, 1997(Senger et al, , 2002 EA-1 Monoclonal antibody α 6 Murine model of melanoma cells (Ruiz et al, 1993) SiRNAs Synthetic oligonucleotides α 6 β 4 MDA-MB-231 breast carcinoma cell line (Lipscomb et al, 2003) Valproic (Verheul et al, 2008) Preceding, and contrary, to these findings is that perlecan the precursor molecule from which endorepellin is derived was also found to have anti-angiogenic and tumour suppressing qualities in prostate cancer (Savore et al, 2005). The suppression of perlecan expression with siRNA in the androgen independent bone targeted cell line C4-2B caused a reduction in colony size and the cohesiveness of transfected sub-clones in anchorageindependent growth assays.…”

Section: Drugmentioning

confidence: 99%